exemestane


Also found in: Medical, Wikipedia.
Related to exemestane: letrozole, Fulvestrant
Translations

exemestane

n exemestano
References in periodicals archive ?
2-3 years of tamoxifen followed by 5 years of an aromatase inhibitor; exemestane in the analysis) would be the economically preferred one.
An international study of postmenopausal women with early-stage cancer found that those who took tamoxifen for 30 months and then switched to the drug exemestane for an identical period were one-third less likely to suffer a recurrence than those consuming tamoxifen for the entire time.
Merrimack Pharmaceuticals, a company that provides cancer medicines, tools and information on the diagnosis and treatment of cancer, has completed patient enrolment in a Phase 2 study evaluating the efficacy of MM-121 in combination with exemestane against exemestane alone in breast cancer, according to reports on Friday.
Recent data from the International Exemestane Study found small absolute differences in overall survival (1.4% at 5 years and 2.4% at 8 years) between women who switched to the aromatase inhibitor (AI) exemestane after 2-3 years of adjuvant tamoxifen and those who continued treatment with the antiestrogen (Eur.
SAN ANTONIO -- Adjuvant exemestane appears to have little effect on cognitive function in postmenopausal women with breast cancer, but women on adjuvant tamoxifen perform significantly worse than do healthy controls in several cognitive domains after I year of treatment, based on results of a sub-study of the TEAM (Tamoxifen Exemestane Adjuvant Multicenter) trial.
The increase averaged 5.9% in women on exemestane (Aromasin), a steroidal AI, and 8.1% in those on the nonsteroidal AIs anastrozole (Arimidex) or letrozole (Femara).
Using progesterone receptor (PgR) status does not help in deciding between aromatase inhibitor and tamoxifen as central analyses of the Arimidex or Tamoxifen Alone or in Combination (ATAC) and BIG1-98 studies, and in a different scenario the Intergroup Exemestane Study (IES), have suggested that although oestrogen receptor (ER)-positive/PgR-negative breast cancer is associated with a worse prognosis than ER-positive/PgR-positive breast cancer, PgR status is not useful for selection of treatment with aromatase inhibitor or tamoxifen [1-3].
For many women, hormone therapy is treatment with the drug tamoxifen, or, for postmenopausal women, an aromatase inhibitor, such as anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin).
is introducing Aromasin (exemestane tablets), the first oral inactivator for treating postmenopausal women with advanced breast cancer whose tumors have stopped responding to tamoxifen therapy.
Pharmaceutical company Novartis Pharmaceutical Corporation announced on Friday that the US Food and Drug Administration (FDA) has approved Afinitor (everolimus) tablets for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ breast cancer) in combination with exemestane after failure of treatment with letrozole or anastrozole2.
She and her colleagues reviewed prescription, herbal, and over-the-counter medications reported in baseline questionnaire data from the Consortium on Breast Cancer Pharmacogenomics randomized clinical trial that evaluated the pharmacogenetics and toxicities of exemestane and letrozole.
The Intergroup Exemestane Study (IES) shows a borderline significant improvement in overall survival in the subset of steroid hormone receptor-positive or unknown breast cancer.